Amlodipine better than lisinopril? How one randomized clinical trial ended fallacies from observational studies

被引：23

作者：

Messerli, Franz H. ^{[1
]}

Staessen, Jan A.

机构：

[1] St Lukes Roosevelt Hosp, Div Cardiol, Hypertens Program, New York, NY 10019 USA

[2] Katholieke Univ Leuven, Studies Coordinat Ctr, Div Hypertens & Cardiovasc Rehabil, Dept Cardiovasc Dis, Louvain, Belgium

来源：

HYPERTENSION | 2006年 / 48卷 / 03期

关键词：

D O I：

10.1161/01.HYP.0000238045.76905.94

中图分类号：

R6 [外科学];

学科分类号：

1002 ; 100210 ;

摘要：

引用

页码：359 / 361

页数：3

共 19 条

[1] Angioedema due to angiotensin-converting enzyme inhibitors [J].

Agostoni, A ;

Cicardi, M ;

Cugno, M ;

Zingale, LC ;

Gioffré, D ;

Nussberger, J .

IMMUNOPHARMACOLOGY, 1999, 44 (1-2) :21-25

[2] Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE):: a randomised trial against atenolol [J].

Dahlöf, B ;

Devereux, RB ;

Kjeldsen, SE ;

Julius, S ;

Beevers, G ;

de Faire, U ;

Fyhrquist, F ;

Ibsen, H ;

Kristiansson, K ;

Lederballe-Pedersen, O ;

Lindholm, LH ;

Nieminen, MS ;

Omvik, P ;

Oparil, S ;

Wedel, H .

LANCET, 2002, 359 (9311) :995-1003

[3] Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA):: a multicentre randomised controlled trial [J].

Dahlöf, B ;

Sever, PS ;

Poulter, NR ;

Wedel, H ;

Beevers, DG ;

Caulfield, M ;

Collins, R ;

Kjeldsen, SE ;

Kristinsson, A ;

McInnes, GT ;

Mehlsen, J ;

Nieminen, M ;

O'Brien, E ;

Östergren, J .

LANCET, 2005, 366 (9489) :895-906

[4] Rationale and design for the antihypertensive and lipid lowering treatment to prevent heart attack trial (ALLHAT) [J].

Davis, BR ;

Cutler, JA ;

Gordon, DJ ;

Furberg, CD ;

Wright, JT ;

Cushman, WC ;

Grimm, RH ;

LaRosa, J ;

Whelton, PK ;

Perry, HM ;

Alderman, MH ;

Ford, CE ;

Oparil, S ;

Francis, C ;

Proschan, M ;

Pressel, S ;

Black, HR ;

Hawkins, CM .

AMERICAN JOURNAL OF HYPERTENSION, 1996, 9 (04) :342-360

[5]

Dean DE, 2001, J FORENSIC SCI, V46, P1239

[6]

Furberg CD, 2002, JAMA-J AM MED ASSOC, V288, P2981

[7] Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial [J].

Julius, S ;

Kjeldsen, SE ;

Weber, M ;

Brunner, HR ;

Ekman, S ;

Hansson, L ;

Hua, TS ;

Laragh, J ;

McInnes, GT ;

Mitchell, L ;

Plat, F ;

Schork, A ;

Smith, B ;

Zanchetti, A .

LANCET, 2004, 363 (9426) :2022-2031

[8]

Kim S, 2000, PHARMACOL REV, V52, P11

[9] Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipid-lowering treatment to prevent heart attack trial [J].

Leenen, Frans H. H. ;

Nwachuku, Chuke E. ;

Black, Henry R. ;

Cushman, William C. ;

Davis, Barry R. ;

Simpson, Lara M. ;

Alderman, Michael H. ;

Atlas, Steven A. ;

Basile, Jan N. ;

Cuyjet, Aloysius B. ;

Dart, Richard ;

Felicetta, James V. ;

Grimm, Richard H. ;

Haywood, L. Julian ;

Jafri, Syed Z. A. ;

Proschan, Michael A. ;

Thadani, Udho ;

Whelton, Paul K. ;

Wright, Jackson T. .

HYPERTENSION, 2006, 48 (03) :374-384

[10]

Lewington S, 2002, LANCET, V360, P1903, DOI 10.1016/S0140-6736(02)11911-8

← 1 2 →